Our business strategy

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

We have transformed our pipeline and returned to growth and, as a result of continued pipeline delivery and commercial execution, we are now entering a new stage of our journey. This is focused on enhanced innovation and the delivery of life-changing medicines that contribute value to patients and society.

The fundamentals of our strategy are clear. We focus on innovative science and leadership in our three main therapy areas: Oncology; Cardiovascular, Renal and Metabolism; and Respiratory diseases. Backed by a global presence, with strength in Emerging Markets, particularly China, we have a portfolio of specialty and primary care medicines.

At the same time, the world around us is changing and the burden of disease is increasing. We are responding by increasing our focus on growth through innovation - being more patient-centric, doing more with technology, digital and data, and advancing more cutting-edge science.

All this is reflected in our three strategic priorities.  

  • Accelerate innovative science

    Advancing high-potential late-stage pipeline projects, pursuing the next wave of disruptive biology and accelerating efforts in AI, data science and digital technology

  • Deliver growth and therapy area leadership

    Driving growth, impacting and improving the whole patient journey and collaborating with the funders of healthcare

  • Be a great place to work

    Our commitment to society and our people